Extracellular vesicles and methods of using
The present disclosure relates to materials and methods for extracellular vesicle (e.g., exosome)-mediated delivery of cargo (e.g., endogenous and/or exogenous) to non-bovine mammalian (e.g., human) cells. For example, exosomes isolated from bovine milk for delivering cargo to non-bovine mammalian (e.g., human) cells are provided.
1. A milk exosome comprising:
a biological membrane surrounding a lumen, wherein the biological membrane comprises one or more glycoprotein(s) comprising galactose,
wherein the biological membrane is modified such that it has an increased number of the one or more glycoprotein(s) comprising galactose as compared with the natural biological membrane of the milk exosome.
2. The milk exosome of claim 1 , wherein the biological membrane is further modified such that it includes one or more glycoprotein(s) that is not naturally present in the natural biological membrane.
3. The milk exosome of claim 1 , wherein the biological membrane is further modified such that one or more of its native glycoprotein(s) is altered.
4. The milk exosome of claim 1 , wherein the one or more glycoprotein(s) comprising galactose are native glycoprotein(s).
5. The milk exosome of claim 3 , wherein the one or more native glycoprotein(s) is altered such that the number of glycan residues present on the one or more glycoprotein(s) is decreased.
6. The milk exosome of claim 3 , wherein the one or more native glycoprotein(s) is altered such that it comprises a modified glycan.
7. The milk exosomes of claim 6 , wherein the modified glycan comprises at least one carbohydrate moiety that differs from that of the glycan in the native glycoprotein(s).
8. The exosome of claim 6 , wherein the modified glycan comprises one or more D- or L-glucose, erythrose, fucose, mannose, lyxose, gulose, xylose, arabinose, ribose, 2′-deoxyribose, glucosamine, lactosamine, polylactosamine, glucuronic acid, sialic acid, sialyl-Lewis X (SLex), N-acetyl-glucosamine, N-acetyl-galactosamine, neuraminic acid, N-glycolylneuraminic acid (Neu5Gc), N-acetylneuraminic acid (Neu5Ac), an N-glycan chain, an O-glycan chain, a Core 1, Core 2, Core 3, or Core 4 structure, or a phosphate- or acetate-modified analog thereof or a combination thereof.
9. The exosome of claim 1 , wherein uptake of the milk exosome into a mammalian cell is altered as compared with the uptake of a corresponding milk exosome having its natural biological membrane.
10. The exosome of claim 9 , wherein uptake of the milk exosome into a mammalian cell is increased.
11. The exosome of claim 9 , wherein the mammalian cell is selected from an intestinal cell, venous endothelial cell or other endothelial cell, immune cell, macrophage, intestinal mucosa, peripheral cell of the liver, spleen, lung, brain, kidneys, or pancreas, cancer cell, or fetal cell.
12. The exosome of claim 1 , wherein the stability of the milk exosome in the gastrointestinal tract, systemic circulation, lymphatic circulation, intracellular conditions, or other tissues or organs of a subject is increased as compared with an exosome having its natural biological membrane.
13. The exosome of claim 1 , wherein the stability of the milk exosome under physiological conditions in a subject is increased as compared with a milk exosome having its natural biological membrane.
14. The milk exosome of claim 1 , further comprising an exogenous cargo encapsulated in said lumen.
15. The milk exosome of claim 1 , wherein the milk exosome further comprises an miRNA or mRNA that is biologically active in a mammal.
16. The milk exosome of claim 1 , wherein the milk exosome is isolated from sheep, goat, camel, horse, donkey, reindeer, yak, buffalo, or bovine Ecew) milk or colostrum.
17. The milk exosome of claim 14 , wherein the exogenous cargo is selected from one or more nucleic acid molecules, polypeptides, lipids, vitamins, minerals, small molecules, pharmaceuticals, hormones, or enzymes.
18. The milk exosome of claim 14 , wherein the exogenous cargo comprises a therapeutic agent.
19. The milk exosome of claim 18 , wherein the therapeutic agent is selected from mRNAs, polypeptides, miRNAs, miRNA antagonists, nutrients, antibiotics, cancer drugs, activators of Toll-like receptors, or molecules capable of delivery to macrophages.
20. The milk exosome of claim 18 , wherein the therapeutic agent is a cancer drug selected from a chemotherapeutic, an immunotherapeutic, a hormone therapeutic, or a targeted therapeutic.
21. A method of altering the uptake of a milk exosome into a mammalian cell or tissue, the milk exosome having a biological membrane comprising one or more glycoprotein(s) comprising galactose, comprising modifying the biological membrane of the exosome such that is has an increased number of the one or more glycoprotein(s) comprising galactose as compared with the natural biological membrane of the milk exosome.
22. The method of claim 21 , wherein the uptake of the milk exosome into a mammalian cell or tissue is increased.
23. The method of claim 21 , wherein the uptake of the milk exosome into a mammalian cell or tissue is selectively increased in a targeted mammalian cell or tissue.
24. The method of claim 21 , wherein the biological membrane is further modified such that it includes one or more glycoprotein(s) that is not naturally present in the natural biological membrane.
25. The method of claim 21 , wherein the biological membrane is further modified such that one or more of its native glycoprotein(s) is altered.
26. The method of claim 25 , wherein the one or more native glycoprotein(s) is altered such that the number of glycan residues present on the glycoprotein(s) is increased.
27. The method of claim 25 , wherein the one or more native glycoprotein(s) is altered such that the number of glycan residues present on the glycoprotein(s) is decreased.
28. The method of claim 21 , wherein the mammalian cell is selected from an intestinal cell, venous endothelial cell or other endothelial cell, immune cell, macrophage, intestinal mucosa, peripheral cell of the liver, spleen, lung, brain, kidneys, or pancreas, cancer cell, or fetal cell.
29. A method of targeting a milk exosome to a selected mammalian cell or tissue, the milk exosome having a biological membrane comprising one or more glycoprotein(s) comprising galactose, comprising modifying the biological membrane of the milk exosome such that it has an increased number of the one or more glycoprotein(s) comprising galactose as compared with the natural biological membrane of the milk exosome.